ନୂଆଦିଲ୍ଲୀ: ଦେଶର ଅଗ୍ରଣୀ କୋଭିଡ ଟିକା ଉତ୍ପାଦନକାରୀ ଫାର୍ମା କମ୍ପାନୀ ଭାରତ ବାୟୋଟେକକୁ ଆଉ ଏକ ବଡ ସଫଳତା । ସଂସ୍ଥା ବିକଶିତ କରିଥିବା ଇଣ୍ଟ୍ରାନାଜାଲ ଭ୍ୟାକସିନକୁ (intranasal vaccine by Bharat Biotech )ଜରୁରୀକାଳୀନ ବ୍ୟବହାର ଅନୁମତି ପ୍ରଦାନ କରିଛି DCGI । ଏଥିସହିତ ଭାରତରେ ପ୍ରଥମ ନାଜାଲ ଟିକା ଭାବେ ଏହା ଉପଲବ୍ଧ ହେବାକୁ ଯାଉଛି (intranasal vaccine by Bharat Biotech intranasal vaccine by in India)। ଏହି ଅନୁମୋଦନ ନେଇ କେନ୍ଦ୍ର ସ୍ବାସ୍ଥ୍ୟ ଓ ପରିବାର କଲ୍ୟାଣ ମନ୍ତ୍ରୀ ମନସୁଖ ମାଣ୍ଡଭ୍ୟ ସୂଚନା ଦେଇଛନ୍ତି । ଭାରତର କୋଭିଡ ବିରୋଧୀ ଲଢେଇକୁ ଏହା ବଳ ଯୋଗାଇଇବା ନେଇ ସୂଚନା ଦେଇଛନ୍ତି କେନ୍ଦ୍ର ସ୍ବାସ୍ଥ୍ୟମନ୍ତ୍ରୀ ।
-
Big Boost to India's Fight Against COVID-19!
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022 " class="align-text-top noRightClick twitterSection" data="
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.
">Big Boost to India's Fight Against COVID-19!
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.Big Boost to India's Fight Against COVID-19!
— Dr Mansukh Mandaviya (@mansukhmandviya) September 6, 2022
Bharat Biotech's ChAd36-SARS-CoV-S COVID-19 (Chimpanzee Adenovirus Vectored) recombinant nasal vaccine approved by @CDSCO_INDIA_INF for primary immunization against COVID-19 in 18+ age group for restricted use in emergency situation.